Every 8-K that scPharmaceuticals Inc. (SCPH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SCPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCPH filings page.
scPharmaceuticals Inc. agreed to be acquired by MannKind Corporation under a merger where each scPharmaceuticals share was purchased for $5.35 in cash plus one non-tradable contingent value right (CVR) that can pay up to $1.00 upon achieving specified regulatory and net‑sales milestones. The purchaser commenced a tender offer on September 8, 2025, and as of the offer expiration a total of 39,933,692 shares (about 73.47%) were validly tendered and 5,930,025 shares (about 10.91%) were delivered by guaranteed delivery.
The tender satisfied the Merger Agreement minimum condition, Purchaser accepted for payment the validly tendered shares, and the merger closed on October 7, 2025 by merging the purchaser into the company so the company became a direct wholly owned subsidiary of Parent. Outstanding employee equity with exercise prices below the cash amount were cashed out (net of exercise price), and restricted stock units were converted into cash equal to the cash amount plus one CVR per share; payments are to be made promptly and no later than 15 days after the effective time, subject to withholding.
scPharmaceuticals Inc. entered into a financing arrangement with its pending acquirer, MannKind Corporation, by issuing an unsecured promissory note in exchange for a $10.0 million loan. The note matures on the earliest of September 23, 2026, payment of any termination fee under the merger agreement, or completion of a superior transaction if the company terminates the merger to accept such an offer.
Interest on the loan is tied to the rate applicable to MannKind’s SOFR loans under its existing credit agreement, with the applicable margin for the note effectively set at either 4.75% or 5.00%, depending on that agreement. If the credit agreement ends, interest resets to Adjusted Term SOFR plus 4.75%. scPharmaceuticals may prepay the note in full at any time, and the note includes customary covenants limiting additional debt and liens, as well as standard events of default.
scPharmaceuticals (SCPH) entered a definitive merger transaction with MannKind Corporation and its merger subsidiary, accompanied by a related press release. The merger agreement dated August 24, 2025, provides that in-the-money Company Options outstanding immediately before the effective time will be cancelled and converted into a cash payment equal to the excess of the cash merger consideration over each option's exercise price plus one contingent value right (CVR) per underlying share. The CVRs will be nontransferable except for limited exceptions and a register of CVR holders will be maintained. The filing includes typical deal protections restricting the Company from soliciting or recommending alternative acquisition proposals, subject to board fiduciary duties. The document references SEC filings and risk factor disclosures.
scPharmaceuticals Inc. filed an 8-K reporting an amendment to a supply agreement: Amendment 1 to the Supply Agreement dated August 20, 2025 between West Pharmaceutical Services, Inc. and the registrant. The filing includes a cover page interactive data file embedded in the inline XBRL document and is signed by John H. Tucker, President and Chief Executive Officer of scPharmaceuticals Inc.
The filing identifies the amendment document and the parties but does not provide the amendment's financial terms, operational changes, or material effects on the company within the provided excerpt.